Project Grant R01HL172364
Award Date
1/15/25
Completion Date
11/30/28
Dollars Obligated
$550K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Arkansas. The funding supports the development of microphysiological systems to study hypoxic cardiac injury and the molecular pathways activated in oxygen gradients, with the goal of obtaining a comprehensive understanding of the cardiac response to hypoxic injury. Key research activities include using engineering and pharmacological...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $678,445 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program to the University of Maryland, Baltimore (UMB) to investigate the role of the novel factor C5ORF51 (C5X) in regulating cardiomyocyte function and homeostasis. The overarching goal is to determine the mechanisms by which C5X modulates transcription in cardiomyocytes and its impact on adult cardiomyocyte proliferation and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami to conduct research on improving neovascularization (new blood vessel formation) in peripheral arterial disease and critical limb ischemia. The key objectives are to investigate: 1) whether extracellular vesicles mediate the systemic effect of ischemia training on reprogramming bone marrow-derived monocytes, 2) the role...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,158,878 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Rector & Visitors of the University of Virginia. The project aims to develop a novel approach to mitigate intimal hyperplasia, a common complication following angioplasty procedures. The key objectives are to: 1) Resolve the role of ALDH1A3, a metabolic regulator, in impairing endothelial cell function and promoting intimal...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $684,794 to the University of California, Merced to conduct research on the role of the blood vascular system and endothelial cells in the regeneration of the thymus after cytotoxic treatments. The research aims to utilize novel intravital imaging techniques to directly characterize the thymic vascular physiology, define...
This $686,458 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research project to develop a quantitative, predictive model of vascular remodeling. The project aims to elucidate the regulatory networks governing vascular remodeling processes such as angiogenesis and arteriogenesis, with the goal of identifying novel therapeutic targets for cardiovascular diseases. The research will use a...
The National Institutes of Health National Heart Lung and Blood Institute awarded a $511,680 Project Grant to the University of Illinois under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund research from February 2021 through August 2021 to investigate mechanisms by which vascular endothelial cells instruct macrophage fate in inflammatory injury. Specifically, the research will examine how endothelial cell Wnt signaling licenses the differentiation of monocytes...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $3,007,209 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to The University of Texas Health Science Center at Tyler. The grant, awarded on July 15, 2024, will fund research to elucidate the role of GAB2-MALT1-mediated cell signaling in venous thrombogenesis and the development of venous thromboembolism (VTE), which is a major...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $700,398 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of Columbia University in the City of New York. The grant, awarded on July 1, 2024, will fund research to integrate spatial transcriptomics, genetics, and histomorphology for causal inference in atherosclerotic cardiovascular disease. The research aims to apply novel machine learning algorithms to analyze histology images...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $557,649 project grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Nevada, Reno (UNR) to study the molecular regulation of beta-2 integrin activation in neutrophil adhesion and inflammation related to cardiovascular disease. The 5-year research project aims to investigate how the proteins kindlin-3 and talin-1 induce activation of beta-2 integrins, which is a key step in neutrophil recruitment and...